-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), …
Source: www.youtube.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 32Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects - 3 month(s) ago
Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteonecrosis of the jaw for myeloma patients, with some suggestions for prevention and management.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
How I manage bone modifying agents (BMAs) in #myeloma to avoid jaw osteonecrosis: #mmsm - Obtain dental eval before starting BMAs - If pending invasive dental procedure, advise holding BMAs 2-3 months before and after - Dental exams every 6 months Ref: https://t.co/LDIpn3dvlF https://t.co/cpw2e8dj51
-
-
Mashup Score: 5
Abstract. Abstract 4079Background:. In multiple myeloma (MM), lenalidomide has impressive clinical activity in patients with both relapsed/refractory and newly
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Change Factor Newsletter - 3 month(s) ago
In our third and final installment of the Cardinal Healthᵀᴹ 2023 American Society of Hematology (ASH) Annual Meeting News Briefs, we highlight the top abstracts presented in myeloproliferative neoplasms, including trials in acute myeloid leukemia (AML), systemic mastocytosis, and myelofibrosis. These updates in AML include a phase I trial of a fusion vaccine and a phase II/III trial of tuspetinib…
Source: pages.open.cardinalhealth.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5No, Rep. Steve Scalise Didn’t Vote Against Stem Cell Research From Which He Is Now Benefiting - 3 month(s) ago
Claims of hypocrisy miss the mark in a couple of ways.
Source: thedispatch.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9
CAR T-cell therapy and novel agents are being used in earlier treatment lines for NHL, but how do they fit into the evolving treatment landscape? Authors unpack the data supporting the use of CAR T cells in various NHL subtypes.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Chief's Perspective on Physician Burnout - 4 month(s) ago
Despite a happy oncologist being our most precious resource, physician burnout appears to be at an all-time high, and the topic is now a part of nearly every administrative discussion. 1 It is a multidimensional problem that affects physicians at every stage of their career. The study by Singh 2 and colleagues shines the light on junior faculty at a major academic cancer center and raises many important topics for discussion including the changing nature of health care, which is largely beyond the
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Now that MRD is a valid regulatory endpoint in #myeloma following the FDA ODAC meeting today, can we agree on a common testing approach and MRD threshold in which to call absence of MRD across trials? https://t.co/hWgZlrfHza